Immuno-virological Evaluation of Persons Living With HIV (PLWH)

Status Not yet recruiting

Clinical Trial Summary

This is a dual arm (arm 1 and arm 2) multi-centric non-randomized (prospective) study. Two new multicentric cohorts will be set up in 4 Belgian HIV reference centers (UZ Gent, UZ Brussel, University Hospital Liege and St. Pierre Hospital Brussels): cohort 1 will comprise PLWH in whom ART was initiated during acute HIV infection minimum 3 years ago but no more than 10 years ago (short-term ART cohort); cohort 2 will comprise PLWH on ART since >20 years (long-term ART cohort). Participants will be included based on suppressed viremia and uninterrupted ART since initiation. Participants will undergo one blood sampling and one leukapheresis. In and exclusion criteria are described below.

Clinical Trial Description

This project aims to gain new knowledge and insights into the viral reservoir establishment and HIV Latency as well as to develop new powerful tools to study latency reversal, that will ultimately contribute to research into an HIV curative treatment. The study objectives are - To collect and store state of the art peripheral blood samples (60 vials of 50 X106 PBMC's) from two patient cohorts, 10 acute seroconverters and 10 long-term ART-treated patients . - To characterize and compare the latent reservoir in blood samples from both cohorts as for the proviral genome, transcriptome, epigenome and T cell receptor level - To perform an immunological profiling of infected cells. - To evaluate available drugs that induce either a block-and-lock or a shock-and-kill in in vitro interventions using blood samples from both cohorts - To accelerate the negative selection of transcriptionally competent proviruses in vitro and determine the role of the different determinants. - To make all data available for the different partners and integrate all data acquired. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05973825
Study type	Interventional
Source	University Hospital, Ghent
Contact	Linos Vandekerckhove
Phone	+3293323398
Email	linos.vandekerckhove@ugent.be
Status	Not yet recruiting
Phase	N/A
Start date	June 1, 2024
Completion date	July 12, 2029

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03940521` - Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
Completed	`NCT03227731` - Immediate or Deferred Pre-exposure Prophylaxis for HIV Prevention: Safe Options for Pregnant and Lactating Women	Phase 2/Phase 3
Completed	`NCT03570918` - MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy	Phase 1
Not yet recruiting	`NCT06336434` - CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy	Phase 1/Phase 2
Active, not recruiting	`NCT04022967` - ANRS 12372 MODERATO Study	Phase 3
Not yet recruiting	`NCT06337032` - A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments	Phase 4
Not yet recruiting	`NCT06282783` - Studying Topiramate for Re-Activating the HIV-1 Reservoir	Phase 1/Phase 2
Completed	`NCT04711265` - Antibody Response to Prophylactic QHPV Vaccine at 48 Months Among HIV-infected Girls and Boys
Recruiting	`NCT03536234` - Efficacy and Safety of GnRH Analogue Triptorelin for HIV-1 Reservoir Reduction in ART Treated HIV-1 Infected Patients	Phase 2
Completed	`NCT04340388` - Contribution of Dolutegravir to Obesity and Cardiovascular Disease	Phase 4
Withdrawn	`NCT05769569` - Safety and Efficacy of Neutralizing Antibodies and Vaccination for Induction of HIV Remission	Phase 1
Enrolling by invitation	`NCT05584397` - Comparing Immune Activation and Latent HIV Reservoir Size Between People Living With HIV on Tenofovir-containing Versus NRTI-free ART
Not yet recruiting	`NCT04894357` - Impact of V106I on Resistance to Doravirine
Completed	`NCT04388904` - Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)	Phase 4
Completed	`NCT04963712` - Zadaxin and HIV-positive Patients With Immune Reconstitution Disorder	Early Phase 1
Not yet recruiting	`NCT04311957` - Continuation of Protease-Inhibitor Based Second-Line Therapy vs. Switch to B/F/TAF in Virologically Suppressed Adults	Phase 4
Not yet recruiting	`NCT04513496` - Telemedicine in HIV Care in Buenos Aires
Completed	`NCT04568239` - Impact of M184V on the Virological Efficacy to 3TC/DTG (LAMRES)
Not yet recruiting	`NCT04311944` - Early Fast-Track Versus Standard Care for Persons With HIV Initiating TLD	N/A
Completed	`NCT03998176` - Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) in HIV-1 Infected Patients With Active Illicit Substance usE	Phase 4